ZUG, Switzerland, November 5, 2025, MoonLake Immunotherapeutics (NASDAQ:MLTX) ("MoonLake"), a clinical-stage biotechnology company focused on advancing therapies to address significant unmet needs in inflammatory skin and joint diseases, today announced the pricing of an underwritten offering of 7,142,857 Class A ordinary shares at an offering price per share of $10.50. The gross proceeds from the offering to MoonLake, before deducting the underwriting discounts and commissions and other offering expenses payable by MoonLake, are expected to be approximately $75 million. The offering is expected to close on or about November 6, 2025, subject to the satisfaction of customary closing conditions. All of the securities to be sold in the offering are being offered by MoonLake.

MoonLake intends to use the net proceeds from this offering together with its existing cash, cash equivalents and marketable securities, to fund the research and development of sonelokimab and for general corporate purposes.

Leerink Partners is acting as sole bookrunning manager for the offering.

A shelf registration statement relating to these securities has been filed with the Securities and Exchange Commission ("SEC") and became effective on September 11, 2023. A prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Copies of the prospectus supplement and accompanying prospectus may also be obtained, when available, by contacting Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone ...